Ardelyx Inc Total Assets
Ardelyx Inc total assets. Based on the latest financial reports, Ardelyx Inc (ARDX) holds total assets worth $575.89 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Ardelyx Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Ardelyx Inc (2012–2025)
Total assets of Ardelyx Inc from 2012 to 2025. This chart illustrates how Ardelyx Inc's total assets have evolved over time, based on quarterly financial data. See ARDX stock price and chart for real-time trading data and today's change.
Ardelyx Inc - Asset Composition Analysis
Ardelyx Inc Total Assets Breakdown (December 2025)
Ardelyx Inc total assets breakdown as of December 2025. Ardelyx Inc's total assets of $575.89 Million consist of 76.2% current assets and 23.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.6% |
| Accounts Receivable | $71.85 Million | 14.3% |
| Inventory | $17.73 Million | 3.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Ardelyx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Ardelyx Inc (ARDX) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ardelyx Inc's current assets represent 76.2% of total assets in 2025, a decrease from 97.3% in 2012.
- Cash Position: Cash and equivalents constituted 13.6% of total assets in 2025, down from 86.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 14.3% of total assets.
Ardelyx Inc Competitors by Total Assets
Key competitors of Ardelyx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Ardelyx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.34 | 4.30 | 2.23 |
| Quick Ratio | 3.15 | 4.03 | 2.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $309.71 Million | $269.85 Million | $84.61 Million |
Ardelyx Inc - Advanced Valuation Insights
This section examines the relationship between Ardelyx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.58 |
| Latest Market Cap to Assets Ratio | 1.56 |
| Asset Growth Rate (YoY) | 15.1% |
| Total Assets | $501.60 Million |
| Market Capitalization | $782.31 Million USD |
Valuation Analysis
Above Book Valuation: The market values Ardelyx Inc's assets above their book value (1.56x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Ardelyx Inc's assets grew by 15.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ardelyx Inc (2012–2025)
The table below shows the annual total assets of Ardelyx Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $501.60 Million | +15.11% |
| 2024-12-31 | $435.75 Million | +46.43% |
| 2023-12-31 | $297.58 Million | +56.57% |
| 2022-12-31 | $190.07 Million | +26.78% |
| 2021-12-31 | $149.91 Million | -25.62% |
| 2020-12-31 | $201.56 Million | -22.41% |
| 2019-12-31 | $259.78 Million | +41.70% |
| 2018-12-31 | $183.33 Million | +16.10% |
| 2017-12-31 | $157.90 Million | -25.91% |
| 2016-12-31 | $213.13 Million | +82.25% |
| 2015-12-31 | $116.95 Million | +3.11% |
| 2014-12-31 | $113.41 Million | +164.34% |
| 2013-12-31 | $42.90 Million | +13.25% |
| 2012-12-31 | $37.88 Million | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more